Loading patent…
OwnerJuan Saus, Francisco Revert-Rosinventors
Estimating the term…
The present invention provides isolated GPBP-interacting 90 and 130 kDa polypeptides, and portions thereof (GIP90/130 polypeptides), antibodies to the GIP90/130 polypeptides, and pharmaceutical compositions thereof. The present invention also provides isolated GIP90/130 nucleic acid sequences, expression vectors comprising the nucleic acid sequences, and host cells transfected with the expression vectors. The invention further provides methods for detecting the GIP90/130 polypeptides or nucleic acid sequences, methods for inhibiting interactions between GPBP and GIP90/130 polypeptides, between pol k76 and GIP90/130 polypeptides or aggregation of GIP90/130 polypeptides, and methods for treating patients with autoimmune disorders or cancer.
An isolated polypeptide comprising at least 6 amino acids of the amino acid of SEQ ID NO:2.
12-22. (canceled)
An isolated polypeptide selected from the group consisting of SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:34, and SEQ ID NO:38.
An antibody directed against a polypeptide comprising an amino acid sequence of one or more of the amino acid sequences selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, and SEQ ID NO:38.
An isolated nucleic acid sequence comprising a sequence that hybridizes under high stringency conditions to a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:17, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:31, and SEQ ID NO:35.
A method for modifying interactions between GPBP and GIP 90/130 polypeptides and/or pol k76 and GIP 90/130 polypeptides, comprising contacting cells with an amount effective of one or more GIP90/130 polypeptide or an antibody directed against one or more GIP90/130 polypeptide to modify the interaction between GPBP and GIP 90/130 polypeptides and/or pol k76 and GIP 90/130 polypeptides.
A method for modifying aggregation of GIP 90/130 polypeptides comprising contacting cells with an amount effective of one or more GIP90/130 polypeptide or an antibody directed against one or more GIP90/130 polypeptide to modify the aggregation of GIP 90/130 polypeptides.
A method for treating a patient with an autoimmune disorder, comprising modifying the expression or activity of one or more GIP90/130 polypeptides in the patient with the autoimmune disorder.
A method for treating a patient with a tumor, comprising modifying the expression or activity of one or more GIP90/130 polypeptides in the patient with the tumor.
Dependencies are inferred from the claim text.